A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Condition: Triple Negative Breast Cancer Interventions: Drug: Nanosomal Docetaxel Lipid Suspension (75 mg/m2); Drug: Nanosomal Docetaxel Lipid Suspension (100 mg/m2); Drug: Taxotere® (100 mg/m2) Sponsors: Jina Pharmaceuticals Inc.; Intas Pharmaceuticals Limited; Lambda Therapeutic Research Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Docetaxel | Nanotechnology | Study | Taxotere